Смешанная форма недержания мочи: современный взгляд на проблему (обзор клинических рекомендаций)

1. Hampel C, Weinhold D, Benken N et al. Prevalence and Natural History of Female Incontinence. Eur Urol 2007; 32 (Suppl. 2): 3–12.
2. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Cociety. Urology 2003; 61 (1): 37–49.
3. Юренева С.В., Ермакова Е.И., Глазунова А.В. Диагностика и терапия генитоуринарного менопаузального синдрома у пациенток в пери- и постменопаузе (краткие клинические рекомендации). Акушерство и гинекология. 2016; 5. / Iureneva S.V., Ermakova E.I., Glazunova A.V. Diagnostika i terapiia genitourinarnogo menopauzal'nogo sindroma u patsientok v peri- i postmenopauze (kratkie klinicheskie rekomendatsii). Akusherstvo i ginekologiia. 2016; 5. [in Russian]
4. Monz D, Pons M, Hampel C et al. Patien – repoted impact of urinary incontinence. – Results from treatment seeking women in 14 European countries. Maturitas 2005; 52 (2): 25–8.
5. Cameron AP, Heidelbaugh JJ, Jimbo M. Diagnosis and office-based treatment of urinary incontinence in adults. Part one: diagnosis and testing. Ther Adv Urol 2013; 5 (4): 181–7
6. Shah SM, Gaunay GS. Treatment options for intrinsic sphincter deficiency. Nat Rev Urol 2012; 9 (11): 638–51.
7. Geoffrion R. No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy – An Addendum. J Obstet Gynaecol Can 2017; 39 (12): 1221–9.
8. Вишневский Е.Л., Пушкарь Д.Ю., Лоран О.Б. и др. Урофлоуметрия. М., 2004; с. 176–208, 263. / Vishnevskii E.L., Pushkar' D.Iu., Loran O.B. i dr. Urofloumetriia. M., 2004; s. 176–208, 263. [in Russian]
9. Baessler K, Christmann-Schmid C, Maher C et al. Surgery for women with pelvic organ prolapse with or without stress urinary incontinence. Cochrane Database Syst Rev 2018; 8.
10. Petros PE. Mixed urinary incontinence – time to uncouple urgency from stress. Int Urogynecol J 2011; 22 (8): 919–21.
11. Lee JK, Dwver PL, Rosamila A et al. Persistence of urgency and urge urinary incontinence in women with mixed urinary symptoms after midurethral slings: a multivariate analysis. BJOG 2011; 118 (7): 798–805.
12. Stewart F, Berghmans B, Bø K, Glazener CM. Electrical stimulation with non-implanted devices for stress urinary incontinence in women. Cochrane Database Syst Rev 2017; 12.
13. Monteiro S, Riccetto C, Araújo A et al. Efficacy of pelvic floor muscle training in women with overactive bladder syndrome: a systematic review. Int Urogynecol J 2018.
14. Kirchin V, Page T, Keegan PE et al. Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev 2017; 7.
15. Khullar V, Amarenco G, Angulo JC et al. Efficacy and tolerability of mirabegron, a b(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013; 63 (2): 283–95.
16. Chapple C, Kaplan S, Mitcheson H et al. Randomised, double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a b(3)adrenoceptor agonist, in overactive bladder (OAB). Eur Urol 2013; 62 (2): 296–305.
17. The 2017 hormone therapy position statement of The North American Menopause Society NAMS. Menopause 2017; 24 (7).

________________________________________________

1. Hampel C, Weinhold D, Benken N et al. Prevalence and Natural History of Female Incontinence. Eur Urol 2007; 32 (Suppl. 2): 3–12.
2. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the International Continence Cociety. Urology 2003; 61 (1): 37–49.
3. Iureneva S.V., Ermakova E.I., Glazunova A.V. Diagnostika i terapiia genitourinarnogo menopauzal'nogo sindroma u patsientok v peri- i postmenopauze (kratkie klinicheskie rekomendatsii). Akusherstvo i ginekologiia. 2016; 5. [in Russian]
4. Monz D, Pons M, Hampel C et al. Patien – repoted impact of urinary incontinence. – Results from treatment seeking women in 14 European countries. Maturitas 2005; 52 (2): 25–8.
5. Cameron AP, Heidelbaugh JJ, Jimbo M. Diagnosis and office-based treatment of urinary incontinence in adults. Part one: diagnosis and testing. Ther Adv Urol 2013; 5 (4): 181–7
6. Shah SM, Gaunay GS. Treatment options for intrinsic sphincter deficiency. Nat Rev Urol 2012; 9 (11): 638–51.
7. Geoffrion R. No. 353-Treatments for Overactive Bladder: Focus on Pharmacotherapy – An Addendum. J Obstet Gynaecol Can 2017; 39 (12): 1221–9.
8. Vishnevskii E.L., Pushkar' D.Iu., Loran O.B. i dr. Urofloumetriia. M., 2004; s. 176–208, 263. [in Russian]
9. Baessler K, Christmann-Schmid C, Maher C et al. Surgery for women with pelvic organ prolapse with or without stress urinary incontinence. Cochrane Database Syst Rev 2018; 8.
10. Petros PE. Mixed urinary incontinence – time to uncouple urgency from stress. Int Urogynecol J 2011; 22 (8): 919–21.
11. Lee JK, Dwver PL, Rosamila A et al. Persistence of urgency and urge urinary incontinence in women with mixed urinary symptoms after midurethral slings: a multivariate analysis. BJOG 2011; 118 (7): 798–805.
12. Stewart F, Berghmans B, Bø K, Glazener CM. Electrical stimulation with non-implanted devices for stress urinary incontinence in women. Cochrane Database Syst Rev 2017; 12.
13. Monteiro S, Riccetto C, Araújo A et al. Efficacy of pelvic floor muscle training in women with overactive bladder syndrome: a systematic review. Int Urogynecol J 2018.
14. Kirchin V, Page T, Keegan PE et al. Urethral injection therapy for urinary incontinence in women. Cochrane Database Syst Rev 2017; 7.
15. Khullar V, Amarenco G, Angulo JC et al. Efficacy and tolerability of mirabegron, a b(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 2013; 63 (2): 283–95.
16. Chapple C, Kaplan S, Mitcheson H et al. Randomised, double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a b(3)adrenoceptor agonist, in overactive bladder (OAB). Eur Urol 2013; 62 (2): 296–305.
17. The 2017 hormone therapy position statement of The North American Menopause Society NAMS. Menopause 2017; 24 (7).

Е.И.Ермакова*

ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова» Минздрава России. 117997, Россия, Москва, ул. Академика Опарина, д. 4
*ermakova.health@mail.ru

________________________________________________

E.I.Ermakova*

V.I.Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Akademika Oparina, d. 4
*ermakova.health@mail.ru